GW Pharmaceuticals: Committed to making a difference

Chris Tovey - Chief Operating Officer, GW Pharmaceuticals

September 02, 2020.

2 min

11 sec watch

Join Chris Tovey, Chief Operating Officer from his home office as he explains GW Pharmaceutical’s commitment to making a difference during the COVID-19 era.

In this short video, Chris emphasises the strength in the supply chain and the work that has been carried out to ensure a continuity of supply for patients. He goes on to discuss how GW Pharmaceuticals have been adapting their ways of working to ensure customer needs can be fulfilled in this new digital and remote era.

Finally, Chris highlights that despite many clinical trials being put on hold due to the pandemic globally, GW Pharmaceuticals are pushing ahead where safe and possible to do so. Chris explains that GW Pharmaceuticals will be collaborating with key experts in the field to dial up research efforts as we come out of COVID-19 to ensure potential treatments can be made
available for patients and families who so desperately need them.

Video transcript

Hi, my name’s Chris Tovey and I’m GW’s Chief Operating Officer and I’m talking to you
remotely from my home office at the moment. It’s been an amazing few months, shocking in
many places as COVID 19 has sept across the world and has caused a lot of concerns and a lot of issues for many. The biggest concern for me and GW has been to ensure the continuity of supply of our important medicines and we have spent a lot of time with our manufacturing teams, increasing production actually, so I am happy to report and reassure you that we have plenty of stock and we have a strong supply chain behind us that means that patients can definitely expect to have continuity of supply of their important medicines from GW.

Our teams, our NAMS, Neurology Account Managers, and MSLs, have been working from home but I know they’ve been in touch with many of you, answering questions and supporting various programmes that you’ve got running and will continue to do this. We developed our digital technologies and platforms so that we can interact with you, so that we can provide important educational information and so that we can be there when you need us, and we’ll continue to do that. We’ll continue to evolve these platforms to meet your needs.

Finally, research. Research has taken a big hit as many clinical trials have been stopped
around the world for many companies. But what we’re continuing to do in places where we
can, is we are pressing forward with important advances in many different disease areas
where we have product candidates and we’ll do this and as we come out of COVID-19 we will be beginning to dial up our all-important research efforts and we look forward to working
with you, many of you actually, on these programmes.

So it’s a crazy time for all of us but you can guarantee that we are going to support you and
give you all the help that can to care for important patients and to navigate these difficult
times. Thank you.

Receive promotional communications and notifications about open-label extension data, our latest conference activity, key opinions from leading researchers and prescribers in cannabinoid therapy.